dr reddy's glp-1 drugs portfolio 2025 Obesity Market Dr. Reddys Laboratories DMF, CEP,
Description
Aging parents, career demands, kids, relationship challenges
doi: 10.1056/NEJMoa1504720 9 MarsoSPDanielsGHBrown-FrandsenKKristensenPMannJFENauckMAet al
Interest in glucagon-like peptide 1 receptor agonists (GLP-1s) continues to surge due to their effectiveness in reducing body weight and improving metabolic outcomes
Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD 8.92 (11.59 to 6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD 1.49 (2.43 to 0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD 9.95 (13.14 to 6.77))
19 , 201216 (2023) X
